» Articles » PMID: 12932731

The Hunt for Huntingtin Function: Interaction Partners Tell Many Different Stories

Overview
Specialty Biochemistry
Date 2003 Aug 23
PMID 12932731
Citations 226
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by an abnormally elongated polyglutamine (polyQ) tract in the large protein huntingtin (htt). Currently, both the normal function of htt in neurons and the molecular mechanism by which the expanded polyQ sequence in htt causes selective neurodegeneration remain elusive. Research in past years has identified several htt-interacting proteins such as htt-interacting protein 1, Src homology region 3-containing Grb2-like protein 3, protein kinase C and casein kinase substrate in neurons 1, htt-associated protein 1, postsynaptic density-95, FIP-2 (for 14.7K-interacting protein), specificity protein 1 and nuclear receptor co-repressor. These proteins play roles in clathrin-mediated endocytosis, apoptosis, vesicle transport, cell signalling, morphogenesis and transcriptional regulation, suggesting that htt is also involved in these processes.

Citing Articles

Huntingtin interactome reveals huntingtin role in regulation of double strand break DNA damage response (DSB/DDR), chromatin remodeling and RNA processing pathways.

Ratovitski T, Holland C, OMeally R, Shevelkin A, Shi T, Cole R bioRxiv. 2025; .

PMID: 39763784 PMC: 11703178. DOI: 10.1101/2024.12.27.630542.


Exploring the Connection Between Nanomaterials and Neurodegenerative Disorders.

Nanda S, Yi D Micromachines (Basel). 2024; 15(11).

PMID: 39597194 PMC: 11596582. DOI: 10.3390/mi15111382.


Roscovitine, a CDK Inhibitor, Reduced Neuronal Toxicity of mHTT by Targeting HTT Phosphorylation at S1181 and S1201 In Vitro.

Liu H, McCollum A, Krishnaprakash A, Ouyang Y, Shi T, Ratovitski T Int J Mol Sci. 2024; 25(22).

PMID: 39596381 PMC: 11594617. DOI: 10.3390/ijms252212315.


Dysregulation of zebrin-II cell subtypes in the cerebellum is a shared feature across polyglutamine ataxia mouse models and patients.

Bartelt L, Switonski P, Adamek G, Longo F, Carvalho J, Duvick L Sci Transl Med. 2024; 16(772):eadn5449.

PMID: 39504355 PMC: 11806946. DOI: 10.1126/scitranslmed.adn5449.


Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease.

Shafie A, Ashour A, Anwar S, Anjum F, Hassan M Arch Pharm Res. 2024; 47(6):571-595.

PMID: 38764004 DOI: 10.1007/s12272-024-01499-w.